文献速递胸部肿瘤

奥希替尼联合度伐利尤单抗治疗EGFR突变晚期非小细胞肺癌:1b期开放标签多中心试验

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.
PubMed 文献 · J Thorac Oncol · 2022-02-15

TATTON研究为开放标签1b期试验,评估奥希替尼联合度伐利尤单抗治疗EGFR突变晚期非小细胞肺癌。A部分为既往EGFR TKI进展后患者,B部分为一线治疗,因ILD相关不良事件发生率增加,B部分提前终止入组。A部分ORR 43%,B部分ORR 82%,但联合治疗存在ILD相关不良事件潜在风险。

要点

  • A部分ORR 43%(95%CI 23-66),中位DOR 20.4个月;B部分ORR 82%(95%CI 48-98),中位DOR 7.1个月。
  • B部分中位PFS 9.0个月(95%CI 3.5-12.3),因ILD相关不良事件发生率增加提前终止入组。
  • 12例患者(35%)报告ILD相关不良事件,联合治疗存在潜在ILD风险,需谨慎。

核心结论

  • 本研究提示奥希替尼联合度伐利尤单抗存在ILD相关不良事件的潜在风险,进一步研究EGFR TKI联合免疫检查点抑制剂应谨慎。

研究设计与样本

  • 开放标签1b期多中心试验(TATTON,NCT02143466),纳入EGFR突变晚期非小细胞肺癌患者。
  • A部分:既往EGFR TKI进展后接受奥希替尼80 mg每日一次联合度伐利尤单抗3或10 mg/kg每2周一次。
  • B部分:一线接受奥希替尼联合度伐利尤单抗10 mg/kg每2周一次,因ILD相关不良事件发生率增加提前终止入组。
  • 主要终点为安全性,同时评估ORR、最佳总体缓解、DOR和PFS。

主要发现

  • 入组终止前,A部分23例、B部分11例患者接受治疗。
  • A部分和B部分最常见不良事件为腹泻(50%)、恶心(41%)和食欲减退(35%)。
  • 12例患者(35%)报告ILD相关不良事件(肺部疾病、ILD或肺炎)。
  • A部分ORR 43%(95%CI 23-66),中位DOR 20.4个月。
  • B部分ORR 82%(95%CI 48-98),中位DOR 7.1个月,中位PFS 9.0个月(95%CI 3.5-12.3)。

临床怎么用

  • 作者认为,奥希替尼联合度伐利尤单抗存在ILD相关不良事件的潜在风险,进一步研究EGFR TKI联合免疫检查点抑制剂应谨慎。

局限性

  • B部分因ILD相关不良事件发生率增加提前终止入组。
  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: EGFR tyrosine kinase inhibitors (TKIs) are recommended for EGFR-mutated NSCLC treatment. EGFR activation up-regulates programmed death-ligand 1 expression and other immunosuppressive factors in NSCLC, causing immune microenvironment remodeling. Osimertinib (an EGFR TKI) plus durvalumab (programmed death-ligand 1 blockade) was evaluated in the TATTON study (NCT02143466). METHODS: This open-label, phase 1b study enrolled patients with advanced EGFR-mutated NSCLC. In part A, patients who had progressed on a previous EGFR TKI received osimertinib (80 mg once daily) plus durvalumab 3 or 10 mg/kg every 2 weeks. In part B, patients received first-line osimertinib plus durvalumab 10 mg/kg every 2 weeks. However, part B enrollment was terminated early owing to an increased incidence of interstitial lung disease (ILD)-related adverse events (AEs). Safety (primary objective) and preliminary anti-tumor activity determined by objective response rate (ORR), best overall response, duration of response (DOR), and progression-free survival were evaluated. RESULTS: Before enrollment termination, 23 and 11 patients received treatment across parts A and B, respectively. The most common AEs across parts A and B were as follows: diarrhea (50%), nausea (41%), and decreased appetite (35%). A total of 12 patients (35%) reported ILD-related AEs (lung disorder, ILD or pneumonitis). In part A, ORR was 43% (95% confidence interval [CI]: 23-66); median DOR was 20.4 months. In part B, ORR was 82% (95% CI: 48-98), median DOR was 7.1 months, and median progression-free survival was 9.0 months (95% CI: 3.5-12.3). CONCLUSIONS: This study highlighted a potential risk of ILD-related AEs when combining osimertinib with durvalumab. Further research looking to combine EGFR TKIs with immune checkpoint inhibitors should be approached with caution.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ahn MJ, Cho BC, Ou X, et al. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. J Thorac Oncol. 2022. PMID: 35181499. doi:10.1016/j.jtho.2022.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。